Gilad S Gordon
M.D., M.B.A.

Medical Consultant

Experienced pharmaceutical executive with broad strategic and operational expertise in product development and positioning, worldwide regulatory planning and execution, research and commercialization, funds raising and value realization upon exit.

Key achievements as Chief Medical Officer

  • Inviragen: developed and implemented worldwide registration and clinical development strategy for dengue fever and hand/foot/mouth vaccines, leading to a sale to Takeda for $250M and international registration

  • Ligand: developed innovative registration strategy for product for bone marrow transplants, designed pivotal trial that enrolled in record time, clinical lead of team that sold rights for over $50 million to Spectrum Pharmaceuticals

  • FeRx: developed worldwide clinical and registration strategy for liver cancer device/drug combination, resulting in term sheet for $40M from venture capital firm

  • Lung cancer with diagnostic test: developed marketing strategy that lead to 200% increase in sales and developed methods to optimize insurance reimbursement

  • MicroRNA Products: developed clinical and regulatory strategies, designed and implemented clinical trials, assisted with private collaborations and public listing leading to raising over $200M in funding

Major Accomplishments

2004-present
ORRA Group, Boulder, co

President

Consultant to various healthcare organizations with clients ranging from early-stage start-ups where projects involved serving as CEO or Chief Medical Officer to Fortune 100 companies where projects related to directing clinical programs

  • Performed functions of CMO for over 40 companies, resulting in raising over $1B; companies focus included oncology, hematology, immunology, vaccines, diagnostics; started & monitored multi-site/multi-country Phase 1-3 trials, developed global clinical strategy, set up advisory boards, wrote & submitted INDs & NDAs to FDA/EMEA

  • Performed due diligence and provided strategic advice on multiple companies focused on therapeutics, diagnostics and devices; over 20 of which resulted in investments by venture capital firms and hedge funds totaling over $700M

  • Obtained and managed public and private research collaborations worth over $200 million

  • Served as Chief Safety Officer and DSMB member for companies with oncology, immunology & hepatitis products

  • Organized meetings with key regulators worldwide including FDA, EMA, WHO, and Asian/Latin American NRAs

  • Directed multiple health economic and quality of life projects which lead to optimal pricing and increased valuations

  • Lecturer on health economics, public policy, and health care pricing; advisor to state senators on health care reform

2002-2004
FeRx Inc., CO and CA

Vice President of Medical Affairs

Biotechnology company that developed drug delivery systems for human oncology applications

  • Directed all medical aspects of clinical trials for the treatment of hepatocellular carcinoma including pivotal multi-national Phase II/III; completed enrollment in Phase II/III trial 6 months ahead of schedule

  • Clinical lead on “road-show” team that obtained term sheet for $40M funding commitment from venture capital firm

  • Coordinated interactions with the FDA and EMEA, leading to obtaining Orphan Drug designation

2000-2002
Ribozyme Pharmaceuticals, Inc., Boulder, CO

Director, Clinical Research

Biotechnology company that developed ribozymes for human oncology and virology applications

  • Directed team that started five major Phase I and Phase II trials for three products in oncology and hepatitis in two countries; medical monitor for first studies that evaluated role of ribozymes in disease

  • Directed clinical development partnership with two multi-billion dollar partner companies; solidified partnership that led to significant revenues

1998-2000
Independent Consultant, Boulder, CO

Consulting Chief Medical Officer

Assignments included serving as Consulting Chief Medical Officer for a publicly traded biotechnology company and medical advisor to venture capital firms and start-up companies

  • Led team that designed Phase III clinical trials for oncology products and presented plans to FDA for a biotechnology company; client received FDA approval to conduct trials, resulting in $50M clinical development and marketing partnership agreement

  • Performed due diligence on potential investments for venture capital firms; positive recommendations led to investments in healthcare companies specializing in cardiology, diagnostics, and specialty healthcare

  • Developed medical strategies and wrote the business plan for start-up web-based medical information company; efforts led to company receiving early-stage funding

  • Served as member of health economics and outcomes research advisory committees

1996-1998
Bolder Heuristics, Boulder, CO

Vice President, Health Care

Software development company specializing in complex custom software products for medical applications

  • Managed healthcare software development division; grew segment by 300% in 2 years

  • Led team that implemented $2 million telephone-based medical triage application for disease management company that resulted in increased sales, decreased operational costs, and additional outside funding for client

  • Developed strategic business and informatics plan for web-based home healthcare monitoring organization that resulted in client obtaining funding from leading venture capital firms

  • Member of the team that negotiated merger of company with IGS with a valuation of over $100M

1994-1996
MediQual Systems, Inc., Westborough, MA

Medical Director

Leading clinical information system company with over 400 hospital clients and a 30 million patient database

  • Managed 40 person client support (clinical and IT) organization that helped client organizations to interpret and utilize the database to improve clinical decision making and patient care and to decrease costs

  • Started and developed pharmaceutical consulting division that generated in excess of $1 million in first-year revenues

  • Developed new marketing strategies utilizing claims databases that expanded the company’s portfolio of services and leading to over 100% increase in revenue

1991-1994
Synergen, Inc., Boulder, CO

Director, Clinical Research

  • Directed team that reviewed, compiled, and analyzed the Phase III clinical data, leading to un-blinding of the clinical data four months ahead of schedule

  • Led 200-person team that submitted PLA to European regulatory agencies three months ahead of schedule

  • Directed health economics department that conducted collaborative, multi-national cost-effectiveness, quality of life, pharmaco-epidemiology, public policy, and pricing studies; worked widely cited in the literature

1988-1991
Eli Lilly and Company, United Kingdom and Indiana

Clinical Research Physician & Associate Clinical Research Physician

  • Led team that completed pediatric Phase III studies for a new antibiotic, submitted NDA to the FDA, and received FDA approval in record time

  • Led team that completed European Phase III studies for a new antibiotic and submitted dossier to European regulatory agencies; drug received marketing approval in Europe

  • Coordinated team that responded to public accusations and demonstrated the safety of Prozac and Human Insulin. As a result, the FDA strongly supported Lilly and did not take regulatory action against either of the products.

  • Developed new methodology for undertaking cost-effectiveness and quality of life research during Phase II-III clinical trials in both the United States and Europe

Education and Training

  • University of Washington
    M.B.A. - 1988

  • University of Washington
    July 1986 - June 1988
    Senior Fellow - Robert Wood Johnson Clinical Scholars Program

  • University of Colorado Health Sciences Center
    June 1983 - June 1986
    Internship and Residency in Internal Medicine

  • Harvard Medical School/Massachusetts Institute of Technology
    Division of Health Sciences and Technology
    M.D., Cum Laude - 1983

  • Harvard University
    A.B., Magna Cum Laude in Biochemistry - 1979
    John Harvard Scholar - 1975 - 1979

FACULTY APPOINTMENTS and certifications

  • Department of Medicine, University of Colorado Health Sciences Center
    1992 - present
    Clinical Associate Professor of Medicine
    1992 - 2006
    Attending physician - Denver Veteran’s Administration Hospital (1 month per year)

  • Department of Medicine, University of Indiana Medical School
    1988 - 1992
    Assistant Professor of Medicine

  • Diplomate, American Board of Internal Medicine, 1987

  • Medical License: Colorado

Board Memberships

  • Imidex
    Artificial intelligence company to evaluate lung nodules
    2020 – present, member, Scientific Advisory Committee

  • Industrial Labs, Inc.
    Drug and Nutraceutical testing company, $3 million in annual sales
    1994-present, Board member

  • AmideBio
    Biotechnology company focused on protein therapeutics for endocrine applications
    2012 – present, Member of Advisory Board

  • Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center
    Center to promote research on GI cancers
    2012 – present, Chairman of the Advisory Board
    2009 – present, member of the Advisory Board

  • Jewish Family Services of Colorado
    2019 – present, Board member

  • Center for Health, Work and Environment, University of Colorado School of Public Health
    Center to promote workers’ health
    2015- present, Advisory Board member

  • Caring for Colorado Foundation
    (Board appointed by Governor of Colorado)
    Conversion foundation ($180M) focused on improving health care in Colorado
    2015 – 2016, Chairman, Board of Directors
    2013 – 2015, Vice-Chairman, Board of Directors
    2008 – 2016, Board member

  • University of Colorado, Boulder Campus
    2005-2011, Institutional Review Board

Lectures

  • Is the COVID-19 Pandemic Over? Perspectives of HR79 Experts, Harvard University
    June 2021

  • Clinical Development – Therapeutics and Vaccines, SPARK Seminar at University of Colorado
    October 2020

  • Digital event: Confronting a Pandemic; The foundations of reopening, STAT and Harvard Medical School
    May 2020

  • Clinical Development – Therapeutics and Vaccines, SPARK Seminar at University of Colorado
    May 2020

  • Making a Difference Through Bio-Pharmaceutical Research, Harvard Medical School
    February 2019

  • How to Conduct Clinical Research, Surgery Ground Rounds, Abet Hospital, Addis Abba, Ethiopia
    April, 2018

  • Regulatory Considerations: Biopharmaceutical Perspective, Colorado Bioscience Association meeting
    October, 2014

  • Personalized Health Care Second Annual Symposium of the Ruesch Center for the Cure of Gastrointestinal Cancers at the Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
    December, 2012

  • Turning a “Drug” Into a “Therapy,” First Annual Symposium of the Ruesch Center for the Cure of Gastrointestinal & Cancers at the Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
    February, 2010

  • 25 years of Biotechnology: Has it met its promise? 25th Reunion Symposium, Harvard Medical School, Boston, MA
    June 2008

  • 25 years of Biotechnology: Has it met its promise? 25th Reunion Symposium, Harvard Medical School, Boston, MA
    June 2008

  • International Drug Development, Regulatory Affairs Professional Society Meeting, Orlando, FL
    December 2004

  • The Future of American Health Care, 25th Reunion Symposium, Harvard University, Cambridge, MA
    June 2004

  • The FDA – Recent Developments and Successful Strategies, Cooley Godward Life Sciences Roundtable Series 2003, Broomfield, CO
    March 2003

  • Ribozymes: From the Laboratory to the Clinic (All in Colorado!) Department of Medicine, University of Colorado Health Sciences Center, Vail, CO
    September 2001

  • Validation of the Therapeutic Recommendations of the American Thoracic Society Guidelines for Community Acquired Pneumonia (CAP) in Hospitalized Patients, American College of Chest Physicians Annual Meeting, San Francisco, CA
    October 1996

  • Validation of the American Thoracic Society Guidelines for Community Acquired Pneumonia (CAP) in Hospitalized Patients, American Thoracic Society Annual Meeting, New Orleans, LA
    May 1996

  • Methods to Evaluate Cost-Effectiveness in Wound Healing. International Burn Federation Annual Meeting, Maui, Hawaii
    February 1996

  • Demonstrating Product Value Through Pharmaco-Economic Modeling. Medical Marketing Association Annual Meeting, Monterey, California
    June 1995

  • Cost-Effectiveness in Wound Healing. International Burn Federation Annual Meeting, Maui, Hawaii
    April 1995

  • Economic Analysis of Therapies for the Treatment of Sepsis. Knoll Pharmaceutical Managers Meeting, Mt. Olive, New Jersey
    June 1995

  • The Biotechnology Regulatory and Clinical Hurdles. Arthur Andersen Annual High Technology Managers Meeting, San Jose, California
    September 1994

  • Hospital Drug Formularies and Use of Hospital Services. SunHealth Alliance Managers Meeting, Jackson, Florida
    September 1994

  • Evaluating Outcomes Research. Premier Health Alliance Pharmacoeconomics Symposium, Chicago, Illinois
    June 1994

  • Evaluating Outcomes Research for New Product Introductions. Academy of Managed Care Pharmacists, San Diego, California
    May 1993

  • The Use of Cost Effectiveness and Outcome Studies in the Reimbursement Arena. Indigent Patient Programs and Reimbursement Hotlines, Washington, DC
    November 1992

  • Quality in Health Care: The Costs and Benefits of Biotechnology. American Legislative Exchange Council Annual Meeting, Colorado Springs, Colorado
    August 1992

  • Assessment of Quality of Life in Clinical Trials. Drug Information Association Annual Meeting, San Diego, California
    June 1992

  • Health Service Research in the Pharmaceutical Industry - Unparalleled Opportunities. Robert Wood Johnson Foundation Annual Meeting, Ft. Lauderdale, Florida
    November 1990

  • Cost Effectiveness of High Technology Pharmaceuticals. Indiana Pharmacists Association Annual Meeting, Indianapolis, Indiana
    September 1990

  • Methodological Issues in Measuring Indirect Medical Costs. Society of General Internal Medicine, Washington, DC
    May 1990

  • Cost-Competitiveness of a Teaching Hospital as a System of Care. Robert Wood Johnson Foundation Annual Meeting, Miami, Florida
    October 1988

  • Cost-Competitiveness of a Teaching Hospital as a System of Care. American Federation of Clinical Research, Washington DC
    May 1988

  • Intranasal Administration of Deferoxamine to Iron-Overloaded Patients. Society of Pediatric Research, Washington, DC
    May 1985

  • Intranasal Administration of Insulin as an Alternative to Parenteral Therapies. American College of Physicians, Washington, DC
    March 1985

  • Intranasal Administration of Insulin as an Alternative to Parenteral Therapies. Sixth International Beilinson Symposium on Future Trends in Juvenile Diabetes, Tel-Aviv, Israel
    October 1984

  • Effective Nasal Absorption of Insulin from Insulin-Bile Salt Aerosols in Normal and Diabetic Subjects. American College of Physicians - Colorado Chapter, Denver, Colorado
    March 1984

Publications

Abstracts

  • "Whole Recombinant Yeast-Based Immunotherapy for Treatment of Chronic Hepatitis C infection Induces Dose-Dependent T Cell Responses and therapeutic effects without vector neutralization" AASLD. Nov 11 – 15, 2005, San Francisco, CA.
    Haller, A., King, T., Lu, Y., Kemmler, C., Bellgrau, D., Gordon, G., Appelian, D., A Franzusoff, A. Rodell, T., and R. Duke, R.

  • "Preclinical Development of Yeast-Based Immunotherapy for Chronic Hepatitis Virus Infection." 8th Annual Conference on Vaccine Research. Poster Presentation; May 9-11, 2005; Baltimore MD.
    Haller, A. King, T, Lu, Y., Kemmler, C., Bellgrau, D., Gordon, G., Appelian, D., A Franzusoff, A. Rodell, T., and R. Duke, R.

  • “A novel yeast-based immunotherapeutic product for chronic hepatitis C virus infection”. AASLD Meeting, March 4-5, 2005, Chicago, IL.
    Haller, A, King, T, Lu, Y, Kemmler, C, Gordon, G, Bellgrau, D, Franzusoff, A, Rodell, T, Duke, R. Abstract

  • Interim results from a phase I/II study of hepatic delivery of doxorubicin adsorbed to magnetic targeted carriers (MTC-DOX) in patients with unresectable HCC,. 2004 Gastrointestinal Cancers Symposium, Abstract #130, 2004.
    Koda, J, Li, H., Qin, S., Ye, S., Gordon, G.S., Owens-Grillo, J., Sun, Y.

  • Preliminary Results From a Phase I/II Study of Hepatic Delivery of Doxorubicin Adsorbed to Magnetic Targeted Carriers (MTC-DOX) in Patients with Unresectable HCC, 2004 Gastrointestinal Cancers Symposium, Abstract #55, 2004.
    Li, H., Qin, S., Ye, S.L., Koda, J., Gordon, G.S., Owens-Grillo, J., Sun, Y.

  • A Phase I/II Trial to Determine The Safety, Tolerance, and Preliminary Activity of Intrahepatic Delivery of Doxorubicin Hydrochloride Adsorbedto Magnetic Targeted Carriers (MTC-DOX) in Patients With Metastatic Cancer in the Liver, European Cancer Conference, 2003.
    Just, R., Hoh, C., Vogl, T., Neese, P., Doemeny, J., Schechter, M., Varney, R., Stanton, W., Schiemann, M., Goldfarb, P., Venook, A., Koda, J., Owens-Grillo, J., Gordon, G.

  • “A Phase I Study of HERZYMETM, an Anti-HER2 Ribozyme, in Patients with HER2 Overexpressing Cancers,” American Association of Cancer Research, 2003.
    Gelmon, K, Chia, S, Chi, K, D’Aloisio, D Ayers, S, Moore, M, Sykes, D, Radka, S, Hurliman, M, Kong, L, Gordon, G, Maloney, L, Lee, P

  • “Safety Analysis of a Phase I Study of HeptazymeTM, A Nuclease Resistant Ribozyme Targeting Hepatitis C (HCV) RNA,” American Association for the Study of Liver Diseases, HEPATOLOGY 34: 333A, 2001.
    Sandberg, J., Rossi, S., Gordon, G., Turik, M., Braun, D., Aitchison, R., Babcock, S., Hansen, B., Wright, T., Blatt, L.

  • “ANGIOZYME, A Synthetic Ribozyme Targeting the mRNA of VEGFR-1: Clinical Update.” Society for Biologic Therapy Annual Meeting. Bethesda, MD. Nov. 9-11, 2001.
    Cowens, W., et al.

  • “ANGIOZYME™ Pharmacokinetic and Safety Results: A Phase I/II Study in Patients with Refractory Solid Tumors.” Annual Meeting of the American Society for Clinical Oncology. San Francisco, CA. May 11-14, 2001.
    Weng, D., Weiss, P., Kellackey, C., Ganapathi R., Parker, V., Gordon, G., Usman, N., Cowens, W., Smith, J., Jackson, T., Radka, S.

  • "Whole Recombinant Yeast-Based Immunotherapy for Treatment of Chronic Hepatitis C infection Induces Dose-Dependent T Cell Responses and therapeutic effects without vector neutralization" AASLD. Nov 11 – 15, 2005, San Francisco, CA.
    Haller, A., King, T., Lu, Y., Kemmler, C., Bellgrau, D., Gordon, G., Appelian, D., A Franzusoff, A. Rodell, T., and R. Duke, R.

  • "Preclinical Development of Yeast-Based Immunotherapy for Chronic Hepatitis Virus Infection." 8th Annual Conference on Vaccine Research. Poster Presentation; May 9-11, 2005; Baltimore MD.
    Haller, A. King, T, Lu, Y., Kemmler, C., Bellgrau, D., Gordon, G., Appelian, D., A Franzusoff, A. Rodell, T., and R. Duke, R.

  • “A novel yeast-based immunotherapeutic product for chronic hepatitis C virus infection”. AASLD Meeting, March 4-5, 2005, Chicago, IL.
    Haller, A, King, T, Lu, Y, Kemmler, C, Gordon, G, Bellgrau, D, Franzusoff, A, Rodell, T, Duke, R. Abstract

  • Interim results from a phase I/II study of hepatic delivery of doxorubicin adsorbed to magnetic targeted carriers (MTC-DOX) in patients with unresectable HCC,. 2004 Gastrointestinal Cancers Symposium, Abstract #130, 2004.
    Koda, J, Li, H., Qin, S., Ye, S., Gordon, G.S., Owens-Grillo, J., Sun, Y.

  • Preliminary Results From a Phase I/II Study of Hepatic Delivery of Doxorubicin Adsorbed to Magnetic Targeted Carriers (MTC-DOX) in Patients with Unresectable HCC, 2004 Gastrointestinal Cancers Symposium, Abstract #55, 2004.
    Li, H., Qin, S., Ye, S.L., Koda, J., Gordon, G.S., Owens-Grillo, J., Sun, Y.

  • A Phase I/II Trial to Determine The Safety, Tolerance, and Preliminary Activity of Intrahepatic Delivery of Doxorubicin Hydrochloride Adsorbedto Magnetic Targeted Carriers (MTC-DOX) in Patients With Metastatic Cancer in the Liver, European Cancer Conference, 2003.
    Just, R., Hoh, C., Vogl, T., Neese, P., Doemeny, J., Schechter, M., Varney, R., Stanton, W., Schiemann, M., Goldfarb, P., Venook, A., Koda, J., Owens-Grillo, J., Gordon, G.

  • “A Phase I Study of HERZYMETM, an Anti-HER2 Ribozyme, in Patients with HER2 Overexpressing Cancers,” American Association of Cancer Research, 2003.
    Gelmon, K, Chia, S, Chi, K, D’Aloisio, D Ayers, S, Moore, M, Sykes, D, Radka, S, Hurliman, M, Kong, L, Gordon, G, Maloney, L, Lee, P

  • “Safety Analysis of a Phase I Study of HeptazymeTM, A Nuclease Resistant Ribozyme Targeting Hepatitis C (HCV) RNA,” American Association for the Study of Liver Diseases, HEPATOLOGY 34: 333A, 2001.
    Sandberg, J., Rossi, S., Gordon, G., Turik, M., Braun, D., Aitchison, R., Babcock, S., Hansen, B., Wright, T., Blatt, L.

  • “ANGIOZYME, A Synthetic Ribozyme Targeting the mRNA of VEGFR-1: Clinical Update.” Society for Biologic Therapy Annual Meeting. Bethesda, MD. Nov. 9-11, 2001.
    Cowens, W., et al.

  • “ANGIOZYME™ Pharmacokinetic and Safety Results: A Phase I/II Study in Patients with Refractory Solid Tumors.” Annual Meeting of the American Society for Clinical Oncology. San Francisco, CA. May 11-14, 2001.
    Weng, D., Weiss, P., Kellackey, C., Ganapathi R., Parker, V., Gordon, G., Usman, N., Cowens, W., Smith, J., Jackson, T., Radka, S.

  • “Inpatient Platelet Use and Costs for Patients with Solid Tumors: A Comparison Between Refractory and Non-Refractory Patients,” American Society of Clinical Oncology, May, 1997.
    J. Kallich, M. Erder, J. LaBrecque, D. Throop, A. Tucker, L. Berberian, G. Gordon

  • “Inpatient Platelet Use and Costs for Patients with Hematological Diseases: A Comparison between Refractory and Non-Refractory Patients,” American Society of Hematology, December 1996
    J. Kallich, M. Erder, J. LaBrecque, L. Berberian, A. Joyce, A. Tucker, D. Throop, G. Gordon

  • “Validation of the Therapeutic Recommendations of the American Thoracic Society Guidelines for Community Acquired Pneumonia (CAP) in Hospitalized Patients,” American College of Chest Physicians, October, 1996
    Gordon, G.S., Niederman, M., Throop, D., Berberian, L., Bass, J., Alemayehu, D., Mellis, S.

  • “Validation of the American Thoracic Society (ATS) Guidelines for Community Acquired Pneumonia in Hospitalized Patients”, American Thoracic Society, May, 1996.
    Gordon, G.S., Throop, D., Berberian, L., Niederman, M., Bass, J., Alemayehu, D., and Mellis, S.

  • “Evaluating Red Blood Cell Transfusions Utilizing a Large Clinical Database,” Association for Pharmaco-Economic Research, May, 1996.
    Ollendorf, D., Throop, D., Berberian L., and Gordon, G.

  • “Epidemiology of Thrombocytopenia, Platelet Transfusion Utilization, and Costs,” American Society of Hematology, December 1995.
    Erder, H., LaBrecque, J., Gordon, G.S., Ollendorf, D., Throop, D., and Kallich, J.

  • “Evaluating Red Blood Cell Transfusions Utilizing a Large Clinical Database,” Drug Information Association, June, 1995.
    Gordon, G.S., Throop, D., Steen, P.

  • “Quality of Life in Active Rheumatoid Arthritis (RA): Patients Receiving Recombinant Human Interleukin-1 Receptor Antagonists (rh1L1-ra, Anakinra)”, Arthritis Rheum, 37:S249, 1994.
    Carlin, R., Noe, L.L., Lookabaugh, J., Witt, K., Campion, G., and Gordon, G.S.

  • “An Analysis of Hospital Length of Stay in a Double-Blind, Placebo-Controlled Clinical Trial of Recombinant Human Interleukin-1 Receptor Antagonist (Anakinra) in the Treatment of Patients with Sepsis Syndrome,” Pharmacotherapy, 14:371, 1994.
    Noe, L.L., Pribble, J.P., Barriere, S.L., Drummond, M.F., van Hout, B.A., Bloom, B.S., Levy, H., Opal, S.M., Balk, R.A., Johnson, S., Dhainaut, J.F., and Gordon, G.S.

  • “A comparison of Hospital Resource Efficiency in Patients with Sepsis Treated with Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) or Placebo,” Intensive Care Medicine, 20:S20, 1994.
    Noe, L.L., Pribble, J.P., Levy, H., Opal, S.M., Balk, R.A., Fisher, C.J., Dhainaut, J.F., Bloom, B.S., Barriere, S.L., and Gordon, G.S.

  • “The Impact of Interleukin-1 Receptor Antagonist (IL-1ra) on the Hospital and Intensive Care Unit Length of Stay of Patients with Sepsis Syndrome,” Proceedings of the Society of Critical Care Medicine, 22:A117, 1994.
    Noe, L.L., Pribble, J., Barriere, S., Fisher, C., Dhainaut, J.F., Opal, S., and Gordon G.S.

  • “Hospital Billing Records as a Source for Determining Resource Consumption in the Hospital and in the Intensive Care Unit,” Proceedings of the 9th International Conference on Pharmacoepidemiology, 1993.
    Noe, L.L., Seyid, K., Carlin, B., and Gordon, G.S.

  • “Cost-Effectiveness of Treatment with Interleukin-1 Receptor Antagonist (IL-1ra) in Patients with Sepsis Syndrome,” Clinical Research, 40:254A, 1992.
    Gordon, G.S., Fisher, C.J., Slotman, G.J., Opal, S. M., Pribble, J.P., Stiles, D.M., Catalano, M.A., and the IL-1ra Sepsis Study Group.

  • “Health Services Research in the Pharmaceutical Industry - Unparalleled Opportunities,” Proceeding of the Robert Wood Johnson Annual Meeting, 1990.
    Gordon, G.S., Overhage, M., Franson, T.R., Gordon, G.S., Hsylop, D.L., Kotsanos, J.G., Tierney, W. “Natural History of Treated and Untreated Candidemia,” Abstracts of the ICAAC Meetings, 1989.

  • “An Analysis of Resource Utilization Patterns in Teaching and Non-Teaching Hospitals in Washington State,” Clinical Research, 37:, 1989.
    Gordon, G.S., Sefcik, S.E., and LoGerfo, J.P.

  • “Lack of Difference in Charges Between Teaching and Non-Teaching Hospitals in Settings for Obstetric Care,” Proceedings of the Robert Wood Johnson Annual Meeting, 1988.
    Gordon, G.S., Sefcik, S.E., Provence, M.E., and LoGerfo, J.P.

  • “Lack of Difference in Charges Between Teaching and Non-Teaching Settings for Obstetric Care,” Clinical Research, 36:337A, 1988.
    Gordon, G.S., Sefcik, S.E., Provence, M.E., and LoGerfo, J.P.

  • “Excretion of Iron After Intranasal Administration of Deferoxamine,” Pediatric Research, 20:280A, 1986.
    Gordon, G.S., Ambruso, D.R., Githens, J.H., and Robinson, W.A.

  • “Enhanced Excretion of Iron After Administration of Intranasal Deferoxamine”, Proc. 27th Annual Meeting of the American Society of Hematology, 1985.
    Gordon, G.S., Ambruso, D.R., Githens, J.H., and Robinson, W.A.

  • “Hormonal Influences on the Recurrences of Malignant Melanoma: Should We Treat with Estrogens?” First International Conference on Skin Melanoma, May 1985, Venice. Proceedings of the 1st International Conference on Skin Melanoma, 1985.
    Jonsen, M.E., Gordon, G.S., and Robinson, W.A.

  • “Derivatives of Fusidic Acid: Novel Adjuvants for Transnasal Peptide Absorption,” Clinical Research, 33:288A, 1985.
    Silver, R., Moses, A.C., Carey, M.C., Gordon, G.S., and Flier, J.S.

  • “Intranasal Administration of Insulin via Insulin-Bile Salt Aerosols,” Clinical Paper and Poster Competition for Associates, American College of Physicians, 66th Annual Session, March 1985, Washington, DC. p. 5w, 1985.
    Gordon, G.S., Moses, A.C., Carey, M.C., and Flier, J.S.

  • “Intranasal Administration of Insulin as an Alternative to Parenteral Therapies,” 6th International Beilinson Symposium on Future Trends in Juvenile Diabetes, October, 1984. International Study Group of Diabetes in Children and Adolescents Bulletin, 11:57, 1984.
    Gordon, G.S., Moses, A.C., Carey, M.C., and Flier, J.S.

  • “Transnasal Insulin Delivery: Structure-Function Studies of Absorption Enhancing Adjuvants,” Clinical Research, 32:245A, 1984.
    Moses, A.C., Flier, J.S., Gordon, G.S., Silver, R.D., and Carey, M.C.

  • “Correlation Between Linear Growth Rate and C-Peptide Levels in Newly Diagnosed Diabetic Children.” 22nd Annual Meeting of the ESPE, September, 1983, Budapest. Pediat. Res., 18:117, 1984.
    Laron, Z., Gordon, G.S., Topper, E., Karp, M., and Aurback-Klipper, Y.

  • “Effective Nasal Absorption of Insulin from Insulin-Bile Salt Aerosols in Normal and Diabetic Subjects.” Diabetes Supplement, 32:70A, 1983.
    Moses, A.E., Gordon, G.S., Carey, M.C., and Flier, J.S.

  • “Growth Pattern in Newly Diagnosed Prepubertal Diabetic Children.” 8th Annual Meeting of the International Study Group of Diabetes in Children and Adolescents (ISGD), September, 1982, Nairobi. International Study Group of Diabetes in Children and Adolescents Bulletin, 7:12, 1983.
    Laron, Z., Gordon, G.S., Topper, E., Karp, M., and Aurback-Klipper, Y.

  • “Growth Pattern in Newly Diagnosed Prepubertal Diabetic Children.” Annual Meeting of the Israel Diabetes Associations, December, 1982, Haifa. Israel J. Med. Science, 19:304, 1983.
    Laron, Z., Gordon, G., Topper, E., Karp, M., and Aurback-Klipper, Y.